Why the study?
Does dipyridamole improve platelet hyperaggregability and prostacyclin levels in atherosclerosis patients?
Does dipyridamole improve platelet hyperaggregability and prostacyclin levels in atherosclerosis patients?
Dipyridamole increases erythrocyte prostacyclin load in a dose-dependent manner up to 450 mg daily, though a subset of atherosclerosis patients exhibit resistance.
Answers are grounded in this paper and cite their sources.
450 mg dipyridamole may maximize erythrocyte prostacyclin loading in atherosclerosis; leaves open management of the 10% with persistent hyperaggregability.
This study demonstrates the presence of PGI2 in blood and its influence on platelet retention tests, possibly by the intermediate of a releasing system in the columns, which is followed by a proximate recuperation on the erythrocyte sites after the passage. The presence of prostacyclin on the erythrocyte sites seems to depend upon the red cell deformability in relation to the good condition of their erythrocyte ATP reserve. The load of the erythrocyte sites increases with the daily dose of dipyridamole. The maximum load of the sites appears to be reached with a daily dose of dipyridamole 450 mg. Approximately 10% of the atherosclerosis patients who have been treated by dipyridamole keep their platelet hyperaggregability and their abnormally lowered prostacyclin level.
No takes yet. Share an insight, caveat, or question.
Solvay et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: